Seres Therapeutics, Inc. (MCRB) Return on equity 2016–2025
Seres Therapeutics, Inc. (MCRB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
12.9%FY2025 · since FY2016: -69.0% → 12.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 12.9% | +11.9 pp |
| FY2024 | 1.0% | — |
| FY2022 | -2319.9% | -2270.1 pp |
| FY2021 | -49.9% | +1.1 pp |
| FY2020 | -51.0% | — |
| FY2017 | -147.3% | -78.2 pp |
| FY2016 | -69.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice